Find a Clinical Trial

Showing 1 - 10 of 22 Trials
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    e purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. These regimens will be compared to the treatment regimen of Nivolumab and Ipilimumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination with nivolumab. This is the first study in which BMS- 986249 will be given to humans. Are you Eligible? (Inclusion Criteria) Participant must have a solid...
  • Principal Investigator:

    David P. Horowitz, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    Early Phase I
    The purpose of this study is to find out if giving intravenous (IV) contrast (a liquid that helps with the visibility of organs and blood vessels that is given through the vein with the use of a hollow needle) during a Cone Beam Computed Tomography (CBCT- a type of computerized X-ray) can help people who have image guided radiation therapy (IGRT) for the treatment of abdominal and pelvic tumors. Are you Eligible? (Inclusion Criteria) For inclusion in this study subjects: 1. Must be greater than or equal to 18 years of age. 2. Will require image guided external beam radiotherapy to abdominal...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food...
  • Principal Investigator:

    Susan E. Bates, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of the combination of the study drugs MM-398 and ABT-888 (veliparib). MM-398 has been approved by the FDA for advanced pancreatic cancer. ABT-888 (veliparib) has been tested in participants with various tumor types. This study tests different doses of the combination of these drugs to see which combination of doses is safer in people. There will be about 48 people taking part in this study. Are you Eligible? (Inclusion Criteria) Patients must have pathologically confirmed diagnosis of a solid tumor cancer for which there is no known standard...
  • Principal Investigator:

    Matthew Alfred Ingham, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The goal of this study is to determine at what dose the study treatment (ASP9801) is safe and tolerated in study participants with cancer who have tumors that cannot be removed (unresectable) or have spread (metastasized) to a different part of the body. This will be done by enrolling small groups of participants to receive different doses of the study treatment, starting with a very small dose and gradually increasing. The study treatment is given by an injection directly into the tumor. The dose amount you receive will depend on the group you are assigned to. When the safe dose is...
  • Principal Investigator:

    Brian Henick, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if the study treatment called RO7198457 (PCV) can be safely given to patients with cancer. PCV is a personalized cancer vaccine. Participants will either received PCV alone or in combination with atezolizumab. Are you Eligible? (Inclusion Criteria) Participants must have confirmed cancer. Participants must have had treatment for their disease before or have a disease that does not have standard therapy. Participants must be in good physical shape. This means that participants must be able to walk, care for themselves, and do light physical activities...
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The primary purposes of this research study are to learn the safety and tolerability of the investigational drug, XmAb23104 for up to eight dose levels; if the XmAb23104 works in treating tumors like the one that you have; and the side effects from XmAb23104 that occur in order to find the maximum tolerated dose or recommended dose for treating your type of tumor. XmAb23104 is an investigational drug that is designed to activate your own cells to kill your tumor. XmAb23104 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This primary purpose of this study is to find the recommended dose of LGK974 and PDR001 that can be safely given to adult patients who have advanced metastatic pancreatic cancer, or triple negative breast (TNB) cancer, or melanoma, lung squamous cell cancer, esophageal squamous cell cancer, cervical squamous cell cancer, or head and neck squamous cell cancer (HNSCC). Are you Eligible? (Inclusion Criteria) Age 18 years or older Diagnosis of locally advanced or metastatic cancer that has progressed despite standard therapy Willingness and ability to comply with all study procedures
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This research study is studying a drug called AGEN2373 as a possible treatment for advanced cancer. The study drug targets cells that are a part of the body’s immune system to block a protein called anti-CD137 agonist antibody. Blocking this protein is believed to improve the ability of your immune system to fight your cancer. This drug has been tested in animals. This is the first time that the Study Drug will be given to humans. The study will also evaluate how the body breaks down the study drug (pharmacokinetics or “PK”) and what is the effect of the study drug on the...
  • Principal Investigator:

    Matthew Alfred Ingham, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to test the safety of different doses of BA3011 and to find out what effects, good and/or bad, that it has on advanced solid tumor cancers that has tested positive for the AXL protein. AXL is a protein found on certain types of cancer cells. This research study will choose the dose amount that should be studied in the future and test the dose on a greater number of participants. The researchers will test how the body absorbs and processes different doses of BA3011 by taking blood samples.In addition to receiving BA3011, you will also be administered a granulocyte...

Pages